Edition:
United States

Curis Inc (CRIS.O)

CRIS.O on Consolidated Issue listed on NASDAQ Global Market

2.68USD
17 Feb 2017
Change (% chg)

$0.04 (+1.52%)
Prev Close
$2.64
Open
$2.67
Day's High
$2.72
Day's Low
$2.65
Volume
358,674
Avg. Vol
566,208
52-wk High
$3.72
52-wk Low
$1.34

CRIS.O

Chart for CRIS.O

About

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $376.67
Shares Outstanding(Mil.): 140.55
Dividend: --
Yield (%): --

Financials

  CRIS.O Industry Sector
P/E (TTM): -- 47.80 29.39
EPS (TTM): -0.48 -- --
ROI: -83.10 -4.08 13.06
ROE: -109.85 4.84 14.19

BRIEF-Curis Inc exercised its option to extend exclusivity period with Aurigene

* Curis Inc - exercised its option to extend exclusivity period with Aurigene Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-Curis says announces full approval of Roche's Erivedge in European Union

* Says announces full approval of Roche's Erivedge in European Union

Nov 28 2016

BRIEF-Curis reports appointment of Lori Kunkel to board of directors

* Curis announces appointment of Lori A. Kunkel, m.d. to board of directors Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Curis Q3 loss per share $0.21

* Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Curis says Aurigene to invest in co through waiver of payments under collaboration deal

* Aurigene to invest in Curis at premium through waiver of certain milestone payments under collaboration agreement

Sep 07 2016

More From Around the Web

Earnings vs. Estimates